Multidrug resistance in lymphoma: is it time for clinical trials?
Rund
Deborah
D
Hematology Department, Hebrew University-Hadassah Hospital, Ein Kerem, Jerusalem, Israel 91120. rund@cc.huji.ac.il
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D019540:Area Under Curve; D003520:Cyclophosphamide / Q000008:administration & dosage; D003986:Dibenzocycloheptenes / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology*; D011239:Prednisolone / Q000008:administration & dosage; D011804:Quinolines / Q000627:therapeutic use*; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D003986:Dibenzocycloheptenes; D011804:Quinolines; D014750:Vincristine; D004317:Doxorubicin; C095179:zosuquidar trihydrochloride; D003520:Cyclophosphamide; D011239:Prednisolone